Market Place
Sourcing Support
60 Degrees Pharma Expands Tafenoquine Clinical Trial for Babesiosis
11 Dec 2024 //
GLOBENEWSWIRE
60 Degrees Pharma Plans Arakoda® Pilot Before US Launch Expansion
03 Oct 2024 //
GLOBENEWSWIRE
60 Degrees Pharma Closes $4M Private Placement At-Market Under Nasdaq
06 Sep 2024 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals Announces $4M Private Placement
04 Sep 2024 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results
14 Aug 2024 //
GLOBENEWSWIRE
60 Degrees Pharma Supports UK`s SJ733 Study With ARAKODA NDA Access
12 Aug 2024 //
GLOBENEWSWIRE
60 Degrees Pharma Signs Agreements For Tafenoquine Babesiosis Trial Sites
19 Jul 2024 //
GLOBENEWSWIRE
60 Degrees Pharma Gets IRB Approval For Tafenoquine In Babesiosis
09 Jul 2024 //
GLOBENEWSWIRE
GSK, MMV Launch Single-Dose Cure For P. Vivax Malaria In Brazil And Thailand
06 Jul 2024 //
PHARMABIZ
First Patient Enrolled in 60 Degrees Pharma Trial of Tafenoquine for Babesiosis
27 Jun 2024 //
GLOBENEWSWIRE
60 Degrees Receives FDA Orphan Drug Designation for Tafenoquine
11 Jun 2024 //
GLOBENEWSWIRE
Tafenoquine Trial For Babesiosis To Start At Tufts First Such Study
30 May 2024 //
GLOBENEWSWIRE
60 Degrees Outlining Tafenoquine Babesiosis Trial Plan
08 May 2024 //
GLOBENEWSWIRE
60 Degrees Receives FDA Comments on Tafenoquine Clinical Trial Protocol
02 May 2024 //
GLOBENEWSWIRE
60 Degrees Pharma to Sponsor Pilot Study of Tafenoquine for Treatment of CB
03 Apr 2024 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use
20 Feb 2024 //
GLOBENEWSWIRE
60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine
22 Jan 2024 //
GLOBENEWSWIRE
60 Degrees Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine
26 Dec 2023 //
GLOBENEWSWIRE
60 Degrees Pharma Announces Type C Meeting with FDA
15 Nov 2023 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19
12 Oct 2023 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine
22 Aug 2023 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine
15 Aug 2023 //
GLOBENEWSWIRE
60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine
31 Jul 2023 //
GLOBENEWSWIRE
60 Degrees Pharma Awarded U.S. Patent Covering Tafenoquine
26 Apr 2023 //
GLOBENEWSWIRE
Positive PII Data for ARAKODA in Patients with Mild-Moderate COVID-19 Disease
21 Jun 2022 //
PRNEWSWIRE
Novel Malaria Treatment for Children Receives First Approval
15 Mar 2022 //
NYTIMES
ARAKODA Clinical Safety, Tolerability Confirmed in Long-Term Safety Study
19 Nov 2021 //
PRNEWSWIRE
Data Safety Monitoring Board Recommends Completion of Phase II Study of ARAKODA®
12 Oct 2021 //
PRNEWSWIRE
GSK, MMV filing for Kozenis in paediatric populations with Plasmodium
08 Jan 2021 //
PRESS RELEASE
60 Degrees Pharma Announces +ve Results of Cell Culture Testing ARAKODA
14 Jul 2020 //
BUSINESSWIRE
Brazil becomes first malaria endemic country to approve tafenoquine
31 Oct 2019 //
PHARMACEUTICAL-TECHNOLOGY
Teva successfully used a rare pediatric PRV to speed the approval for Ajovy
21 Nov 2018 //
RAPS
FDA Approves ARAKODA™ (tafenoquine) tablets for oral use
10 Aug 2018 //
PR NEWSWIRE
FDA AdComm backs GSK’s 1-shot malaria therapy
16 Jul 2018 //
FIERCE BIOTECH
FDA Panel Backs Tafenoquine for `Radical Cure` of Malaria
13 Jul 2018 //
MEDPAGE TODAY
